abiomed , inc .and subsidiaries notes to consolidated financial statements 2014 ( continued ) note 8 .goodwill and in-process research and development ( continued ) the company has no accumulated impairment losses on goodwill .the company performed a step 0 qualitative assessment during the annual impairment review for fiscal 2015 as of october 31 , 2014 and concluded that it is not more likely than not that the fair value of the company 2019s single reporting unit is less than its carrying amount .therefore , the two-step goodwill impairment test for the reporting unit was not necessary in fiscal 2015 .as described in note 3 .201cacquisitions , 201d in july 2014 , the company acquired ecp and ais and recorded $ 18.5 million of ipr&d .the estimated fair value of the ipr&d was determined using a probability-weighted income approach , which discounts expected future cash flows to present value .the projected cash flows from the expandable catheter pump technology were based on certain key assumptions , including estimates of future revenue and expenses , taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development .the company used a discount rate of 22.5% ( 22.5 % ) and cash flows that have been probability adjusted to reflect the risks of product commercialization , which the company believes are appropriate and representative of market participant assumptions .the carrying value of the company 2019s ipr&d assets and the change in the balance for the year ended march 31 , 2015 is as follows : march 31 , ( in $ 000 2019s ) .
[['', 'march 31 2015 ( in $ 000 2019s )'], ['beginning balance', '$ 2014'], ['additions', '18500'], ['foreign currency translation impact', '-3789 ( 3789 )'], ['ending balance', '$ 14711']]
note 9 .stockholders 2019 equity class b preferred stock the company has authorized 1000000 shares of class b preferred stock , $ .01 par value , of which the board of directors can set the designation , rights and privileges .no shares of class b preferred stock have been issued or are outstanding .stock repurchase program in november 2012 , the company 2019s board of directors authorized a stock repurchase program for up to $ 15.0 million of its common stock .the company financed the stock repurchase program with its available cash .during the year ended march 31 , 2013 , the company repurchased 1123587 shares for $ 15.0 million in open market purchases at an average cost of $ 13.39 per share , including commission expense .the company completed the purchase of common stock under this stock repurchase program in january 2013 .note 10 .stock award plans and stock-based compensation stock award plans the company grants stock options and restricted stock awards to employees and others .all outstanding stock options of the company as of march 31 , 2015 were granted with an exercise price equal to the fair market value on the date of grant .outstanding stock options , if not exercised , expire 10 years from the date of grant .the company 2019s 2008 stock incentive plan ( the 201cplan 201d ) authorizes the grant of a variety of equity awards to the company 2019s officers , directors , employees , consultants and advisers , including awards of unrestricted and restricted stock , restricted stock units , incentive and nonqualified stock options to purchase shares of common stock , performance share awards and stock appreciation rights .the plan provides that options may only be granted at the current market value on the date of grant .each share of stock issued pursuant to a stock option or stock appreciation right counts as one share against the maximum number of shares issuable under the plan , while each share of stock issued .

Question: assuming the same impact of foreign currency translation as in the fiscal year 2015 , what would be the ending balance of in process \\nr&d assets in fiscal 2016?
Answer: 10922000